The Effect of Milk Protein vs Blends of Milk and Plant Protein on Growth Markers in 7-8 Year Old Healthy Danish Children

NCT ID: NCT03384719

Last Updated: 2021-08-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

129 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-18

Study Completion Date

2018-12-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of PROGRO is to determine which combinations of milk and plant proteins are optimal to promote growth factors in children

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main objective is to assess how different protein blends affect growth factors in children. There is evidence to support that milk protein increases growth in children in both high and low-income countries. Therefore milk protein is often used in food aid for undernourished children in low-income countries. The study investigates if plant protein can partially replace milk protein without affecting growth promotion negatively. Plant protein could potentially reduce food aid costs and at the same time be a more sustainable protein source.

The PROGRO study is a 3-arm randomized, controlled trial. The effect of consuming 35 g pure milk protein/day is compared to intake of 35 g milk and rapeseed protein/day (ratio 30:70 and 54:46, respectively) in 7-8 year old healthy Danish children. The intervention period is 4 weeks and measurements and blood sampling are performed at baseline, week 1 and week 4. A 3-day weighed dietary intake is recorded before each visit. The primary outcome is Insulin-like growth factor-1 (IGF-1).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Growth Acceleration Growth; Stunting, Nutritional

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study is a randomized, controlled, double-blind, parallel food intervention study with 3 study arms
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

35 g protein (30% milk + 70% rapeseed)

35 g protein per day (30% milk + 70% rapeseed) provided as a powder to be consumed every morning and evening

Group Type EXPERIMENTAL

35 g protein (30% milk + 70% rapeseed)

Intervention Type DIETARY_SUPPLEMENT

The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.

Protein powder ingredients (all are food quality):

* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.

35 g protein (54% milk + 46% rapeseed)

35 g protein per day (54% milk + 46% rapeseed) provided as a powder to be consumed every morning and evening

Group Type EXPERIMENTAL

35 g protein (54% milk + 46% rapeseed)

Intervention Type DIETARY_SUPPLEMENT

The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.

Protein powder ingredients (all are food quality):

* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.

35 g protein (100% milk)

35 g protein per day (100% milk) provided as a powder to be consumed every morning and evening

Group Type ACTIVE_COMPARATOR

35 g protein (100% milk)

Intervention Type DIETARY_SUPPLEMENT

The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.

Protein powder ingredients (all are food quality):

* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

35 g protein (30% milk + 70% rapeseed)

The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.

Protein powder ingredients (all are food quality):

* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.

Intervention Type DIETARY_SUPPLEMENT

35 g protein (54% milk + 46% rapeseed)

The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.

Protein powder ingredients (all are food quality):

* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Rapeseed protein isolate: Isolexx® (BioExx, Saskatoon, Canada)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.

Intervention Type DIETARY_SUPPLEMENT

35 g protein (100% milk)

The daily amount of 35 g of protein is provided as a powder. The powder is packed in two separate sachets to be consumed in the morning and evening. Each sachet contains approximately 60 g of powder. The powder is mixed with liquid before intake.

Protein powder ingredients (all are food quality):

* Milk protein: Skimmed milk powder (Arla Foods, Viby, Denmark)
* Other ingredients: lactose, sucrose, flavors, artificial sweeteners. The protein powders for each treatment group are standardized to contain the same amount of energy and lactose per day.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 7-8 years
* Healthy\*
* The child is willing to consume protein powder twice a day for 4 weeks
* The child is not a picky eater and so does not mind trying new foods and flavours
* The child speaks Danish in order to understand the study procedures
* The parents read and speak Danish in order to be properly informed about the study procedures
* Written informed consent has been obtained

* The principal investigator, who is blinded to study treatment, will perform a case-by-case medical evaluation of children with any signs of being unhealthy or having any illness or taking medication at the time of admission. If the conditions are considered to potentially affect protein metabolism or growth, the children will not be included. If a child is acutely ill at the scheduled time of study start, the child cannot be included. But the child may be included later when the acute illness has resolved

Exclusion Criteria

* The child drinks more than 350 ml of milk per day
* Known or suspected allergy, sensitization or intolerance to milk (protein or lactose), rapeseed or mustard
* Any acute illness\*
* Chronic illness or disease that may affect protein metabolism or growth\*
* Chronic intake of medicine that may affect protein metabolism or growth\*
* Concomitant participation in other studies involving dietary supplements or blood sampling
* Living in a household with another participating child

* The principal investigator, who is blinded to study treatment, will perform a case-by-case medical evaluation of children with any signs of being unhealthy or having any illness or taking medication at the time of admission. If the conditions are considered to potentially affect protein metabolism or growth, the children will not be included. If a child is acutely ill at the scheduled time of study start, the child cannot be included. But the child may be included later when the acute illness has resolved
Minimum Eligible Age

7 Years

Maximum Eligible Age

8 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Arla Foods

INDUSTRY

Sponsor Role collaborator

University of Aarhus

OTHER

Sponsor Role collaborator

University of Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Christian Mølgaard

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christian Mølgaard, professor

Role: PRINCIPAL_INVESTIGATOR

Department of Nutrition, Exercise and sports, University of Copenhagen

Benedikte Grenov, postdoc

Role: STUDY_CHAIR

Department of Nutrition, Exercise and sports, University of Copenhagen

Anni Larnkjær, PhD

Role: STUDY_CHAIR

Department of Nutrition, Exercise and sports, University of Copenhagen

Camilla T. Damsgaard, Associate Professor

Role: STUDY_CHAIR

Department of Nutrition, Exercise and sports, University of Copenhagen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Nutrition, Exercise and Sports

Copenhagen, Frederiksberg, Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

References

Explore related publications, articles, or registry entries linked to this study.

Grenov B, Larnkjaer A, Ritz C, Michaelsen KF, Damsgaard CT, Molgaard C. The effect of milk and rapeseed protein on growth factors in 7-8 year-old healthy children - A randomized controlled trial. Growth Horm IGF Res. 2021 Oct-Dec;60-61:101418. doi: 10.1016/j.ghir.2021.101418. Epub 2021 Jul 21.

Reference Type RESULT
PMID: 34333391 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D221

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Milk and Plant Protein Digestion
NCT06272331 COMPLETED NA
Food Structure and Satiety
NCT04289883 WITHDRAWN NA
Breakfast for Young Females
NCT04518605 COMPLETED NA